Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study

What Was Tested

This phase 2 clinical trial looks at Somatostatin and Lanreotide.

Lanreotide autogel (LAN) and temozolomide (TMZ) are guidelines-recommended monotherapies for thoracic neuroendocrine tumors (carcinoids; T-NETs), but prospective data for both combined and monotherapies are lacking.

Who Took Part

PubMed tags the participants as both men and women.

Eligible patients had unresectable, locally advanced/metastatic, well-/moderately differentiated T-NETs with radiological progression.

How the Study Was Run

The researchers set it up as an open-label, multicenter and pilot study.

Being open-label, the Somatostatin study did not mask who received what.

More than one site took part, so the participants came from several places.

It is described as a pilot, a small early test of whether a larger Somatostatin study would be practical.

ATLANT was a 12-month, Italian, phase 2, single-arm, open-label, multicenter pilot study.

Main endpoints are disease control rate (DCR) at 9 months (primary; investigator-assessed), median progression-free survival (PFS), biomarkers, and safety.

What Was Measured

Topics PubMed links to this paper include Temozolomide, Neuroendocrine Tumors, Pilot Projects, Carcinoid Tumor, Peptides, Cyclic and Somatostatin.

The authors tagged it with the keywords Disease control rate, Lanreotide autogel, Progression-free survival, Therapy and Thoracic neuroendocrine tumors.

What This Means in Plain Language

The paper is an open-label, multicenter and pilot study of Somatostatin and Lanreotide.

Results are reported in around 12 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Neuroendocrinology), a journal based in Switzerland.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.